P2RY4: A drug target and biomarker for uridine nucleotide receptor

Target Name: P2RY4

NCBI ID: G5030

P2RY4

P2RY4: A drug target and biomarker for uridine nucleotide receptor

Introduction

The uridine nucleotide receptor (UOR) is a protein that plays a crucial role in the regulation of intracellular signaling pathways, including DNA replication, cell proliferation, and apoptosis. Mutations in the UOR gene have been linked to various diseases, including cancer, neurodegenerative disorders , and reproductive disorders. Therefore, understanding the function of the UOR and identifying potential drug targets or biomarkers is of great importance.

P2RY4: A unique G protein-coupled receptor

The P2RY4 gene encodes a G protein-coupled receptor (GPCR), which is a family of transmembrane proteins that play a pivotal role in cellular signaling. GPCRs are involved in various signaling pathways, including sensory perception, neurotransmission, and hormone signaling. P2RY4 is a member of the P2Y family of GPCRs, which includes several structurally similar but functionally distinct subfamilies, including P2Y1, P2Y2, P2Y3, and P2Y4.

P2RY4 is a 12-kDa protein that is expressed in various tissues, including brain, heart, skeletal muscles, and tissues. It is highly conserved, with a similar to the P2Y1 subfamily but with some differences in its sequence and structure. P2RY4 is primarily localized to the endoplasmic reticulum (ER) and nuclear membrane, suggesting a role in intracellular signaling pathways.

Function and dysfunction of P2RY4

P2RY4 is involved in the regulation of intracellular signaling pathways, including DNA replication, cell proliferation, and apoptosis. It is a critical receptor for uridine nucleotide (UN), which is an essential cofactor for the protein kinase A1 (PKA1). P2RY4 is activated by UN and can regulate various cellular processes, including cell proliferation, apoptosis, and DNA replication.

P2RY4 signaling is dependent on the presence of a GPCR-interactive protein called SAR125, which is a highly conserved protein that is expressed in various tissues and is involved in the regulation of intracellular signaling pathways. SAR125 is a negative regulator of P2RY4 and can inhibit its activity by binding to its extracellular domain.

Drug targeting P2RY4

P2RY4 is a potential drug target for various diseases, including cancer, neurodegenerative disorders, and reproductive disorders. Drugs that can inhibit P2RY4 activity or enhance its sensitivity to therapeutic agents have the potential to treat these diseases.

P2RY4 has been targeted by several drugs, including inhibitors of UN-activated P2RY4, such as negative regulators like SAR125, and agonists like U-14, which can enhance the activity of P2RY4. Drugs that target the downstream signaling pathways of P2RY4, such as the PI3K/Akt pathway, have also been developed.

Biomarkers for P2RY4

P2RY4 is involved in various signaling pathways, including intracellular signaling pathways, which can be used as biomarkers for various diseases.

1. DNA replication: P2RY4 is involved in the regulation of DNA replication and can be used as a biomarker for cancer, including neuroendocrine carcinoma (NEC), a subtype of neuroendocrine tumors that are characterized by the production of hormones by target cells.
2. Cell proliferation: P2RY4 is involved in the regulation of cell proliferation and can be used as a biomarker for various types of cancer, including breast cancer and colorectal cancer.
3. Apoptosis: P2RY4 is involved in

Protein Name: Pyrimidinergic Receptor P2Y4

Functions: Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP

The "P2RY4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about P2RY4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets